Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer
NCT05910398
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
488
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer Invasive
Interventions
DRUG:
pyrotinib
Sponsor
RenJi Hospital